FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133716191> ?p ?o ?g. }

• W2133716191 endingPage "1461" @default.
• W2133716191 startingPage "1460" @default.
• W2133716191 abstract "Sir, Identification of specific mediators of arterial damage in GCA is crucial to understand its pathogenesis, and may have important clinical implications both for diagnosis and treatment. Thirty-two non-consecutive patients who underwent a temporal artery biopsy for evaluation of GCA were included in this study. Nineteen of the 32 biopsies had histological evidence of GCA. Detailed pathological findings were recorded on every biopsy and assessed using semi-quantitative scales [1]. Patients’ demographic and clinical information was collected. All subjects gave written informed consent. The study was approved by our institutional review board (Wills Eye Institute).In brief, total RNA was isolated from the temporal artery biopsies. The concentration and quality of RNA was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Wilmington, DE, USA). DNA microarray analysis using Affymetrix U133 Plus 2.0 human genome arrays was performed in two temporal artery specimens with histologically proven GCA and two that were negative for GCA. We focused on identifying which of the 23 human MMPs were up-regulated in GCA. To confirm the expression levels of those genes up-regulated in the microarray analysis, relative quantification by real-time PCR was performed in all the 32 temporal artery biopsies, and gene expression between arteries with histological evidence of GCA and controls were compared. Single-strand cDNA was synthesized from total RNA. Real-time PCR SYBR Green assays with pre-designed primers for MMP-2, -9, -12 and GAPDH (SABioscience Corp., Frederick, USA) were run in a Stratagene Mx3000P thermal cycler. All the assays were run in triplicate by an investigator blinded to the pathological and clinical data.Demographic and clinical features of the patients are shown in Table 1. Those who had negative biopsy results were diagnosed with conditions different from GCA based on their clinical manifestations, the negative biopsy, their lack of response to steroid therapy and their clinical evolution. Seven biopsy-negative patients fulfilled the ACR classification criteria for GCA. In the GCA-negative arteries, >80% of the internal elastic lamina (IEL) was preserved, whereas IEL degradation was common in temporal arteries with histological evidence of GCA. Mild intimal hyperplasia was observed in some of the GCA-negative temporal arteries, but all the GCA-positive arteries showed a high level of intimal hyperplasia and in seven (36.8%) of these, the lumen was virtually occluded. Table 1.Demographic and clinical variables of patients with histologically confirmed GCA and patients with negative temporal artery biopsyA total of approximately 2000 genes showed a significant differential level of expression in our microarray analysis. Approximately half of these were up-regulated and half were down-regulated. Among the MMPs, only MMP-12 (fold change = 163; P = 0.003) and MMP-9 (fold change = 21; P = 0.026) showed statistically significant up-regulation in GCA arteries compared with controls by microarray analysis. MMP-2 was also up-regulated in GCA arteries, but this was not statistically significant (P = 0.075). Interestingly, MMP-12 was the fifth most up-regulated gene, when ordered by the level of expression (see Appendix 1 available as supplementary data at Rheumatology Online). MMP-9 occupied the 65th position in that list. Up-regulation of MMP-12 and -9 was confirmed by real-time PCR. The median fold change (interquartile range) for MMP-12 was 67.7 (400.2) in GCA-positive biopsies vs 2.1 (3) in GCA-negative biopsies (P = 0.003). The median fold change for MMP-9 was 20.7 (57.7) in GCA-positive vs 0.06 (0.5) in GCA-negative biopsies. MMP-2 was also relatively up-regulated in GCA arteries [2.19 (4.15)] compared with GCA-negative biopsies [0.89 (1.14)], but this difference was not statistically significant (P = 0.07). Levels of expression of both MMP-9 and -12 correlated with typical GCA pathological findings (see Appendix 2 available as supplementary data at Rheumatology Online).Our study is the first to use a broad-spectrum approach to define which of the 23 human MMPs are associated with histologically proven GCA. We are the first to have identified the overexpression of MMP-12 gene transcripts in GCA lesions.MMP-12 appears to participate in atherosclerosis and aneurysm growth by degradation of the elastic layers and basement membrane [2, 3]. We postulate that this enzyme may also contribute to elastic lamina degradation in GCA. The association of MMP-9 with histologically confirmed GCA has been reported previously [1, 4–8]. MMP-9 likely facilitates both IEL rupture and intimal hyperplasia [1]. Although the association of MMP-2 with GCA is still controversial, most studies have found that MMP-2 is ubiquitously expressed in temporal arteries both with and without vasculitis [1, 4, 6, 7, 9].Despite the limited number of biopsies included in the microarray study, the stringent statistical analysis used and the validation using real-time-PCR give us confidence in our findings. Although MMP mRNA may not correlate perfectly with protein concentration in tissues or enzymatic activity [10], our findings suggest that the potential role of MMP-9 and -12 in GCA pathogenesis deserves further study. Functional studies are needed to determine the specific contribution of these two enzymes in the development of arterial damage in GCA before any conjecture about their use as therapeutic target(s) can be made. Clinical studies will be required to determine whether serum levels of these MMPs are elevated in GCA patients. If so, our preliminary findings might have implications for diagnosis of GCA." @default.
• W2133716191 created "2016-06-24" @default.
• W2133716191 creator A5001902710 @default.
• W2133716191 creator A5019543596 @default.
• W2133716191 creator A5057332758 @default.
• W2133716191 creator A5059049972 @default.
• W2133716191 creator A5066107153 @default.
• W2133716191 creator A5073621138 @default.
• W2133716191 date "2009-09-06" @default.
• W2133716191 modified "2023-09-26" @default.
• W2133716191 title "MMP-12, a novel matrix metalloproteinase associated with giant cell arteritis" @default.
• W2133716191 cites W1985336951 @default.
• W2133716191 cites W1986095161 @default.
• W2133716191 cites W1994815880 @default.
• W2133716191 cites W2020572482 @default.
• W2133716191 cites W2022063420 @default.
• W2133716191 cites W2068205257 @default.
• W2133716191 cites W2074917263 @default.
• W2133716191 cites W2121381593 @default.
• W2133716191 cites W4296979652 @default.
• W2133716191 doi "https://doi.org/10.1093/rheumatology/kep271" @default.
• W2133716191 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2782257" @default.
• W2133716191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19736181" @default.
• W2133716191 hasPublicationYear "2009" @default.
• W2133716191 type Work @default.
• W2133716191 sameAs 2133716191 @default.
• W2133716191 citedByCount "14" @default.
• W2133716191 countsByYear W21337161912014 @default.
• W2133716191 countsByYear W21337161912015 @default.
• W2133716191 countsByYear W21337161912018 @default.
• W2133716191 countsByYear W21337161912019 @default.
• W2133716191 countsByYear W21337161912020 @default.
• W2133716191 countsByYear W21337161912021 @default.
• W2133716191 countsByYear W21337161912023 @default.
• W2133716191 crossrefType "journal-article" @default.
• W2133716191 hasAuthorship W2133716191A5001902710 @default.
• W2133716191 hasAuthorship W2133716191A5019543596 @default.
• W2133716191 hasAuthorship W2133716191A5057332758 @default.
• W2133716191 hasAuthorship W2133716191A5059049972 @default.
• W2133716191 hasAuthorship W2133716191A5066107153 @default.
• W2133716191 hasAuthorship W2133716191A5073621138 @default.
• W2133716191 hasBestOaLocation W21337161912 @default.
• W2133716191 hasConcept C109523444 @default.
• W2133716191 hasConcept C126322002 @default.
• W2133716191 hasConcept C142724271 @default.
• W2133716191 hasConcept C2776015282 @default.
• W2133716191 hasConcept C2776712624 @default.
• W2133716191 hasConcept C2779134260 @default.
• W2133716191 hasConcept C2910007452 @default.
• W2133716191 hasConcept C2991819120 @default.
• W2133716191 hasConcept C55728118 @default.
• W2133716191 hasConcept C71924100 @default.
• W2133716191 hasConceptScore W2133716191C109523444 @default.
• W2133716191 hasConceptScore W2133716191C126322002 @default.
• W2133716191 hasConceptScore W2133716191C142724271 @default.
• W2133716191 hasConceptScore W2133716191C2776015282 @default.
• W2133716191 hasConceptScore W2133716191C2776712624 @default.
• W2133716191 hasConceptScore W2133716191C2779134260 @default.
• W2133716191 hasConceptScore W2133716191C2910007452 @default.
• W2133716191 hasConceptScore W2133716191C2991819120 @default.
• W2133716191 hasConceptScore W2133716191C55728118 @default.
• W2133716191 hasConceptScore W2133716191C71924100 @default.
• W2133716191 hasIssue "11" @default.
• W2133716191 hasLocation W21337161911 @default.
• W2133716191 hasLocation W21337161912 @default.
• W2133716191 hasLocation W21337161913 @default.
• W2133716191 hasLocation W21337161914 @default.
• W2133716191 hasOpenAccess W2133716191 @default.
• W2133716191 hasPrimaryLocation W21337161911 @default.
• W2133716191 hasRelatedWork W2075649552 @default.
• W2133716191 hasRelatedWork W2085396976 @default.
• W2133716191 hasRelatedWork W2133716191 @default.
• W2133716191 hasRelatedWork W2356265827 @default.
• W2133716191 hasRelatedWork W2362160665 @default.
• W2133716191 hasRelatedWork W2368229018 @default.
• W2133716191 hasRelatedWork W2388302505 @default.
• W2133716191 hasRelatedWork W2929685461 @default.
• W2133716191 hasRelatedWork W3010869738 @default.
• W2133716191 hasRelatedWork W3030844330 @default.
• W2133716191 hasVolume "48" @default.
• W2133716191 isParatext "false" @default.
• W2133716191 isRetracted "false" @default.
• W2133716191 magId "2133716191" @default.
• W2133716191 workType "article" @default.